

INOVIQ INVESTOR BRIEFING INVITATION

Melbourne, Australia, 27 June 2023: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), is pleased to invite investors to attend a special online briefing to discuss the Company's announcement (released earlier today) of outstanding clinical data for its SubB2M/CA15-3 test for breast cancer detection.

The briefing will be presented by Chief Executive Officer, Dr Leearne Hinch together with Chief Scientific Officer, Dr Greg Rice.

Session details:

- Date:** Thursday, 29 June, 2023
- Time:** 11:00am Australian Eastern Standard Time (Melbourne Time)
- Format:** Presentation, followed by a Q+A session
- Register:** Participants can register ahead of time via the following link
https://us02web.zoom.us/webinar/register/WN_etcrRaRmT-i0s2NJmpSZWw#/registration

After registering, investors will receive a confirmation email with details on how to join the session.

- ENDS -

Authorised by the Company Secretary, Mark Edwards.

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

ABOUT SUBB2M PLATFORM

SubB2M is an engineered protein that preferentially binds to the pan-cancer biomarker Neu5Gc, found in multiple human cancers. INOVIQ is developing SubB2M blood tests for multiple uses, including monitoring breast and ovarian cancers, and for a general health panel.

SubB2M may enhance the performance of existing tumour marker tests by binding to multiple Neu5Gc sites on the biomarker that amplify the signal and improve sensitivity, and by increasing the cancer specificity to reduce false positives.